Table 4.
Multivariate Analyses
| Risk Factors | Hazard Ratio (95% CI) | P Value |
|---|---|---|
| For mortality: | ||
| Age group (main effect) | Overall test | .0006* |
| Reference group : 18–59 yr | 1 | NA |
| 60–69 versus 18–59 yr | 1.123(1.018–1.239) | .0204* |
| 70+ versus 18–59 yr | 1.353 (1.150–1.593) | .0003 |
| 70+ versus 60–69 yr | 1.205 (1.022–1.420) | .0261* |
| HCTCI | Overall test | <.0001* |
| ≥ 2 versus <2 | 1.279(1.163–1.407) | <.0001* |
| KPS | Overall test | <.0001* |
| 80–90 versus 100 | 1.242 (1.058–1.407) | .0082* |
| <80 versus 100 | 1.640 (1.344–2.002) | <.0001* |
| Time from diagnosis to transplantation | ||
| 12–24 versus 0–12 mo | 1.321 (1.188–1.469) | <.0001* |
| Disease status at transplantation | Overall test | <.0001* |
| VGPR/PR versus CR | 1.313(1.127–1.530) | .0005* |
| SD versus CR | 1.693(1.353–2.119) | <.0001* |
| REL/PROG versus CR | 3.301 (2.647–4.116) | <.0001* |
| For treatment failure/PFS: | ||
| Age group (main effect) | Overall test | .7014 |
| 60–69 versus 18–59 yr | 1.046 (.892–1.226) | .5832 |
| 70+ versus 18–59 yr | 1.131 (.816–1.567) | .4598 |
| 70+ versus 60–69 yr | 1.082 (.776–1.507) | .6433 |
| KPS | Overall test | .0029* |
| 80–90 versus 100 | 1.069 (.817–1.398) | .6279 |
| <80 versus 100 | 1.594 (1.128–2.253) | .0082* |
| Time from diagnosis to transplantation | ||
| 12–24 versus 0–12 mo | 1.294(1.066–1.571) | .0092* |
| Disease status at transplantation | Overall test | <.0001* |
| VGPR/PR versus CR | 1.327 (1.062–1.658) | .0129* |
| SD versus CR | 1.963 (1.423–2.708) | <.0001* |
| REL/PROG versus CR | 3.076 (1.882–5.028) | <.0001* |
| For NRM: | ||
| Age group (main effect) | Overall test | .9734 |
| 60–69 versus 18–59 yr | .921 (.450–1.884) | .8214 |
| 70+ versus 18–59 yr | 1.006 (.232–4.365) | .9941 |
| 70+ versus 60–69 yr | 1.092 (.245–4.866) | .9082 |
| KPS | Overall test | |
| 80–90 versus 100 | 2.890 (.389–21.485) | .2998 |
| <80 versus 100 | 9.554(1.170–78.039) | .0352* |
| Time from diagnosis to transplantation | ||
| 12–24 versus 0–12 mo | 2.158 (.997– 4.668) | .0508 |
| For progression: | ||
| Age group (main effect) | Overall test | .6811 |
| 60–69 versus 18–59 yr | 1.052 (.893–1.238) | .5465 |
| 70+ versus 18–59 yr | 1.136 (.813–1.587) | .4548 |
| 70+ versus 60–69 yr | 1.080 (.769–1.518) | .6561 |
| KPS | Overall test | .0209* |
| 80–90 versus 100 | 1.039 (.792–1.363) | .7847 |
| <80 versus 100 | 1.456 (1.020–2.079) | .0385* |
| Time from diagnosis to transplantation | ||
| 12–24 versus 0–12 mo | 1.259(1.031–1.539) | .0241* |
| Disease status at transplantation | Overall test | <.0001* |
| VGPR/PR versus CR | 1.299 (1.036–1.630) | .0237 |
| SD versus CR | 1.935 (1.939–2.688) | <.0001* |
| REL/PROG versus CR | 3.074 (1.858–5.085) | <.0001* |
*
Significant at level of .05.